Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Kington Capital

Investor type Venture Capital

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 13
Average round size
info
The average size of a deal this fund participated in
$21M
Portfolio companies 12
Rounds per year 2.17
Lead investments 1
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.08
Exits 2
Key employees 1
Stages of investment
Early Stage Venture

Areas of investment

  • Health Care
  • Semiconductor
  • Manufacturing
  • Medical
  • Pharmaceutical
Summary

Kington Capital is the famous VC, which was founded in 2016. The venture was found in Asia in China. The main office of represented VC is situated in the Suzhou.

We also calculated 1 valuable employee in our database.

The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the Kington Capital, startups are often financed by Sequoia Capital China, SBCVC. The meaningful sponsors for the fund in investment in the same round are Temasek Holdings, Northern Light Venture Capital, YuanMing Capital. In the next rounds fund is usually obtained by 6 Dimensions Capital.

The important activity for fund was in 2018. The fund is generally included in 2-6 deals every year. Deals in the range of 10 - 50 millions dollars are the general things for fund. The real fund results show that this VC is 0 percentage points less often commits exit comparing to other companies.

Besides, a startup needs to be aged 4-5 years to get the investment from the fund. We can highlight the next thriving fund investment areas, such as Therapeutics, Biopharma. The fund has exact preference in a number of founders of portfolio startups. Among the most popular portfolio startups of the fund, we may highlight Gracell Biotechnologies, JW Therapeutics, SyMap Medical. For fund there is a match between the country of its foundation and the country of its the most frequent investments - China.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Kington Capital:
Typical Co-investors
Kington Capital is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Kington Capital:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds from China
Funds with similar focus located in China:
Funds with the same geo focus
Funds with similar geography of portfolio companies:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Accel X Central, Central Region, Singapore
Belcube Belgium, Brussels, Brussels Hoofdstedelijk Gewest
Capital6 Eagle -
D'Ieteren Belgium, Brussels, Brussels Hoofdstedelijk Gewest
Eli Lilly Indiana, Indianapolis, United States
Hitachi Ventures Bayern, Germany, München
Incutex Company Builders Argentina, Córdoba, Cordoba
JNKS Investments -
LAUDA -
MetaStable Capital California, San Francisco, United States
Ministry of Health Singapore Central, Central Region, Singapore
REMUS Capital Boston, Massachusetts, United States
Resources Connection California, Costa Mesa, United States
Senshu Ikeda Holdings Japan, Osaka, Osaka Prefecture
Teton Growth Partners Jackson, United States, Wyoming
Think.Health Bavaria, Bayern, Germany
VICTORIA Venture Capital SCR-Pyme S.A. Barcelona, Catalonia, Spain
Vilitas GmbH & Co. KG Aachen, Germany, Nordrhein-Westfalen
WDHB Colorado, Denver, United States

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Qixin Micro Semiconductor

Automotive
Electric Vehicle
Hardware
Manufacturing
Semiconductor
13 Jun 2022 Suzhou, Jiangsu, China

EVAS Intelligence

Autonomous Vehicles
Semiconductor
$30M01 Mar 2022 -

Next Generation Gene Therapeutics

Genetics
Health Care
Medical
Therapeutics
$30M22 Apr 2021 Suzhou, Jiangsu, China

Gracell Biotechnologies

Biotechnology
Health Care
Medical
$85M25 Feb 2019 Gusu District, Jiangsu, China

LanssonPharm

Health Care
Pharmaceutical
$3M29 Jan 2019 Gusu District, Jiangsu, China

Kanova

Biopharma
Pharmaceutical
$17M26 Nov 2018 China, Jiangsu

SyMap Medical

Health Care
Medical Device
$10M12 Nov 2018 China, Jiangsu

Artificial Intelligence
Manufacturing
Semiconductor
$448K20 Aug 2018 Futian District, Guangdong Province, China

JW Therapeutics

Biotechnology
Health Care
Therapeutics
$90M07 Mar 2018 Shanghai, China

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Kington Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: